Model-based medicineProf. Dr. Thomas Neumuth
The medical field of hematology is characterized by highly heterogeneous diseases and disease courses. Nevertheless, clinical trial design, drug development and subsequent therapy are mostly based on the administration of identical therapeutic regimens. As treatment strategies become more precisely tailored to patients, this process becomes more effective, but at the same time causes an enormous amount of complexity in the information that must be considered. Thus, clinical decision-making also depends on whether the treating physician has the appropriate therapeutic experience and access to novel therapies. The goal of KAIT, an artificial intelligence-based platform for therapeutic decision support for patients with myelodysplastic syndrome, acute myeloid leukemia and multiple myeloma, is to support the clinical decision-making process by providing and evaluating relevant information to enable patient-specific and personalized treatment for all patients.